Cangrelor in Patients Undergoing Percutaneous Coronary Intervention After Out-of-Hospital Cardiac Arrest. [PDF]
J Clin MedBackground: Cangrelor provides rapid platelet inhibition, making it a potential option for out-of-hospital cardiac arrest (OHCA) survivors undergoing percutaneous coronary intervention (PCI). However, clinical data on its use after OHCA are limited. This
Ferlini M +18 more
europepmc +2 more sources
Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives [PDF]
, 2017 Cangrelor is an intravenously administered P2Y12 receptor antagonist with very fast, potent, and quickly reversible action. In the CHAMPION PHOENIX trial, cangrelor provided an improved anti-ischemic protection compared with clopidogrel, without ...
Dimitrios Alexopoulos +3 more
core +1 more source
Cangrelor: Safe and Effective for Left Ventricular Assist Device Thrombosis [PDF]
, 2020 Pump thrombosis is a devastating complication of left ventricular assist device implantation as it increases the risk of mortality and morbidity. Early and effective treatment is important to prevent the progression of the clot and to avoid the surgical ...
Jones, Mark +4 more
core +2 more sources
Frontiers in Neurology, 2023 BackgroundThe optimal antiplatelet therapy regimen for certain neuroendovascular procedures remains unclear. This study investigates the safety and feasibility of intravenous dose-adjusted cangrelor in patients undergoing acute neuroendovascular ...
Harsh Desai +20 more
doaj +1 more source
Synthesis and Impurity Research of 2-Thioadenosine Monohydrate
Pharmaceutical Fronts, 2023 2-Thioadenosine monohydrate (1) is a vital intermediate in the synthesis of cangrelor. However, its industrial-scale preparation process and the analysis of the impurities formed during this process remained largely unknown.
Jing-Jing Xiang +4 more
doaj +1 more source
Stroke: Vascular and Interventional Neurology, 2023 Introduction The optimal antiplatelet therapy regimen for certain neuroendovascular procedures remains unclear. This study investigates the safety and feasibility of intravenous dose‐adjusted cangrelor in patients undergoing neuroendovascular procedures.
Rami Z. Morsi +10 more
doaj +1 more source
Switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention. The switching Antiplatelet-6 (SWAP-6) study [PDF]
, 2023 Background: A drug-drug interaction (DDI) may occur when transitioning from intravenous P2Y12 inhibition with cangrelor to oral P2Y12 inhibition with prasugrel. However, this has never been tested in patients undergoing percutaneous coronary intervention
Dominick J. Angiolillo +18 more
core +1 more source
Cangrelor: an emerging therapeutic option for patients with coronary artery disease [PDF]
, 2014 Item does not contain fulltextOBJECTIVES: To perform a systematic up-to-date review and critical discussion of potential clinical applications of cangrelor based on its pharmacologic properties and the main findings from randomized clinical studies ...
Kubica, J. +9 more
core +1 more source
CRT-100.12 Risk of Bleeding Among Cangrelor-Treated Patients Administered Upstream P2Y12 Inhibitor Therapy [PDF]
, 2023 Introduction: Little is known about the use of cangrelor in patients with MI who are treated with an oral P2Y12 inhibitor upstream prior to cardiac catheterization.
Bhatt, Deepak +20 more
core +1 more source
Low dose intravenous cangrelor versus glycoprotein IIb/IIIa inhibitors in endovascular treatment of tandem lesions [PDF]
, 2023 Intravenous (IV) periprocedural antiplatelet therapy (APT) for patients undergoing acute carotid stenting during mechanical thrombectomy (MT) is not fully investigated.
Rodriguez-Calienes, A. +53 more
core +1 more source